ClinicalTrials.gg
CompletedNCT01727700Updated Feb 13, 2015Results posted

Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

A Phase 3 interventional study of Aripiprazole and Placebo in Tourette's Disorder and Tic Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 75 sites in 9 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-02-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.

Enrollment
3rd of 10
133 · median 97
Started
2012
the only one that year
Phase 3
7 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
6 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing aripiprazole in Tourette Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 7th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing aripiprazole in Tourette Syndrome as a file.
02

Study summary

The goal of the current trial is to determine efficacy and safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.

Read the detailed description

Tourette's Disorder is a neuropsychiatric condition that is characterized by the appearance of tics that can be simple or complex in nature. A tic is a sudden, rapid, recurrent, non-rhythmic, stereotyped motor movement or vocalization. There are a very limited number of medications approved for the treatment of Tourette's Disorder. The goal of the current trial is to obtain efficacy, safety, and tolerability data in a controlled condition of a Once-daily aripiprazole formulation in children and adolescents with Tourette's Disorder. The trial has an 8-week long double-blind treatment period after a pretreatment (screening/washout phase), and the subjects will be followed up for 1 month after the last treatment. The Once-daily tablet formulation that will be evaluated in this trial represents a daily dosage regimen that is intended to be administered to children and adolescents.

03

Conditions studied

  • Tourette's Disorder
  • Tic Disorder

Keywords

  • Tourette Syndrome
  • Basal Ganglia Diseases
  • Brain Diseases
  • Central Nervous System Diseases
  • Tic Disorders
  • Tics
  • Movement Disorders
  • Mental Disorders
  • Aripiprazole
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female, 7 to 17 year old (inclusive) at the time of signing consent
  • meets diagnostic criteria for Tourette's Disorder
  • Presenting tic symptoms cause impairment in the subject's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships
  • Females of must have a negative pregnancy test, must be practicing acceptable double-barrier methods of and must not be pregnant or lactating
  • Written obtained from a legally acceptable representative \& informed assent at Screening as applicable by trial center's IRB/IEC
  • The subject, designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator

Exclusion criteria

Exclusion Criteria:

  • Clinical presentation and/or history, consistent with another neurologic condition that may have accompanying abnormal movements
  • History of schizophrenia, bipolar disorder, or other psychotic disorder
  • Subject receiving psychostimulants for treatment of ADD/ADHD and who have developed and/or had exacerbations of tic disorder after initiation of stimulant treatment
  • Currently meets criteria for a primary mood disorder
  • Severe Obsessive Compulsive Disorder (OCD)
  • Taken aripiprazole within 30 days of the Screening visit
  • Received any agent in a clinical trial within 30 days prior to Screening, enrolled in studies 31-12-272, 31-12-273, 31-12-274; or who were randomized into a clinical trial with Once-daily aripiprazole at any time
  • History of neuroleptic malignant syndrome
  • Sexually active patients not using 2 approved methods of
  • Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug)
  • Risk of committing suicide
  • Body weight lower than 16 kg
  • Taken neuroleptic or antiparkinson drugs \< 14 days prior to randomization
  • Requiring cognitive behavioral therapy (CBT) for Tourette's during trial
  • Subject meets DSM-IV-TR criteria for any significant psychoactive substance use disorder within the past 3 months
  • Positive drug screen
  • Subject requires medications not allowed per protocol
  • Use of CYP2D6 and inhibitors or CYP3A4 inducers within 14 days prior to dosing and for duration of trial
  • Use of herbal medications of any kind and nutritional or dietary supplements for Tourette's disorder within 7 days prior to dosing and for the duration of the trial
  • Inability to swallow tablets or tolerate oral medication
  • Abnormal laboratory test results, vital signs and results
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo Once-Daily

    Drug: Placebo

  • Experimental
    Aripiprazole 5 mg or 10 mg

    Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily

    Drug: Aripiprazole

  • Experimental
    Aripiprazole 10 mg or 20 mg

    Aripiprazole 10 mg 20 mg Immediate Release Once-Daily

    Drug: Aripiprazole

Interventions

  • Once-daily, tablet

    Also known as: Abilify

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).

    The YGTSS is a semi-structured clinical interview designed to measure current (time frame of the past 1 week) tic severity. This scale consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each, including number, frequency, intensity, complexity, and interference. Summation of these 10 scores (ie, 0-50) provides a TTS that was the primary outcome measure in this trial. The YGTSS ranking of impairment score rated on a 50-point scale anchored from 0 (no impairment) to 50 (severe impairment) to assess impairment experienced in areas of self-esteem, family life, social acceptance, and school scores. This is a fully validated scale in adults and has become a standard instrument for the evaluation of the severity of TD in children.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change in Clinical Global Impressions Scale-Tourette's Syndrome (CGI-TS) Score at Week 8.

    To assess CGI-TS severity, the rater or physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" However, the evaluation of illness was limited to manifestations of TD only. Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The change score was obtained from CGI-TS improvement scale assessment: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Week 8

  2. Mean Change From Baseline to Endpoint (Week 8) in Total YGTSS Score

    The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A reduction in Total YGTSS score from baseline represents an improvement in symptoms.

    Time frame: Baseline to Week 8

  3. Mean Change From Baseline to Endpoint (Week 8) in CGI-TS Severity Score

    The CGI-TS Severity scale (range 0-7) is a single-item rating score, with higher scores representing greater severity or less improvement. A response of 0 (not assessed) is considered and handled as missing data.

    Time frame: Baseline to Week 8

  4. Response Rate

    Clinical response is defined as \> 25% improvement from baseline to Week 8 in YGTSS TTS or a CGI-TS Change score of 1 \[very much improved\] or 2 \[much improved\] at Week 8. Response will be considered as missing only if both YGTSS TTS and CGI-TS change score are missing. As long as one of them is non-missing, response outcome will be determined based on the non-missing score.

    Time frame: Week 8

  5. Treatment Discontinuation Rate

    Treatment discontinuation rate will be calculated as the number of discontinued participants (ie, those who were withdrawn from the trial without completing the Week 8 visit) over the number of all randomized participants.

    Time frame: Week 8

07

Results

Posted Feb 13, 2015

Participant flow

This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial in children and adolescents (aged 7-17 years) with Tourette's disorder (TD). 171 participants were screened, of which 133 were randomized to treatment.

Participant flow — Overall Study
MilestoneAripiprazole Low DoseAripiprazole High DosePlacebo
Started444544
Completed423542
Not completed2102
Withdrew: Adverse event071
Withdrew: Particpant withdrew consent031
Withdrew: Protocol violation200

Outcome measures

PrimaryChange From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).

The YGTSS is a semi-structured clinical interview designed to measure current (time frame of the past 1 week) tic severity. This scale consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings are made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics each, including number, frequency, intensity, complexity, and interference. Summation of these 10 scores (ie, 0-50) provides a TTS that was the primary outcome measure in this trial. The YGTSS ranking of impairment score rated on a 50-point scale anchored from 0 (no impairment) to 50 (severe impairment) to assess impairment experienced in areas of self-esteem, family life, social acceptance, and school scores. This is a fully validated scale in adults and has become a standard instrument for the evaluation of the severity of TD in children.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).
Units on a scaleAripiprazole Low DoseAripiprazole High DosePlacebo
Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).-13.35 ± 1.59-16.94 ± 1.61-7.09 ± 1.55
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Mixed Models Analysis · p = 0.0020 (The Hochberg procedure was used to adjust for multiplicity.) · Treatment difference: -6.26 · 95% CI -10.18 to -2.34Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.
  • Aripiprazole High Dose vs Placebo · Mixed Models Analysis · p = <0.0001 (The Hochberg procedure was used to adjust for multiplicity.) · Treatment difference: -9.85 · 95% CI -13.84 to -5.86Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.
SecondaryChange in Clinical Global Impressions Scale-Tourette's Syndrome (CGI-TS) Score at Week 8.

To assess CGI-TS severity, the rater or physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" However, the evaluation of illness was limited to manifestations of TD only. Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The change score was obtained from CGI-TS improvement scale assessment: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Week 8
Reported as:
Least squares mean · Units on a scale
Change in Clinical Global Impressions Scale-Tourette's Syndrome (CGI-TS) Score at Week 8.
Units on a scaleAripiprazole Low DoseAripiprazole High DosePlacebo
Change in Clinical Global Impressions Scale-Tourette's Syndrome (CGI-TS) Score at Week 8.2.12 ± 0.212.13 ± 0.213.15 ± 0.2
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Mixed Models Analysis · p = 0.0001 (The Hochberg procedure was used to adjust for multiplicity.) · Treatment difference: -1.03 · 95% CI -1.54 to -0.52Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.
  • Aripiprazole High Dose vs Placebo · Mixed Models Analysis · p = 0.0002 (The Hochberg procedure was used to adjust for multiplicity.) · Treatment difference: -1.02 · 95% CI -1.54 to -0.49Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.
SecondaryMean Change From Baseline to Endpoint (Week 8) in Total YGTSS Score

The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A reduction in Total YGTSS score from baseline represents an improvement in symptoms.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint (Week 8) in Total YGTSS Score
Units on a scaleAripiprazole Low DoseAripiprazole High DosePlacebo
Mean Change From Baseline to Endpoint (Week 8) in Total YGTSS Score-26.69 ± 3.34-32.80 ± 3.39-13.43 ± 3.27
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Mixed Models Analysis · p = 0.0017 (Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.) · Treatment difference: -13.26 · 95% CI -21.43 to -5.08
  • Aripiprazole High Dose vs Placebo · Mixed Models Analysis · p = <0.0001 (Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.) · Treatment difference: -19.37 · 95% CI -27.70 to -11.04
SecondaryMean Change From Baseline to Endpoint (Week 8) in CGI-TS Severity Score

The CGI-TS Severity scale (range 0-7) is a single-item rating score, with higher scores representing greater severity or less improvement. A response of 0 (not assessed) is considered and handled as missing data.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Endpoint (Week 8) in CGI-TS Severity Score
Units on a scaleAripiprazole Low DoseAripiprazole High DosePlacebo
Mean Change From Baseline to Endpoint (Week 8) in CGI-TS Severity Score-1.35 ± 0.19-1.47 ± 0.19-0.55 ± 0.19
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Mixed Models Analysis · p = 0.0010 (Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.) · Treatment difference: -0.80 · 95% CI -1.27 to -0.33
  • Aripiprazole High Dose vs Placebo · Mixed Models Analysis · p = 0.0002 (Treatment, week, treatment by week interaction, region, and weight group were fixed categorical effects; baseline value as a fixed covariate.) · Mmrm: -0.92 · 95% CI -1.41 to -0.44
SecondaryResponse Rate

Clinical response is defined as \> 25% improvement from baseline to Week 8 in YGTSS TTS or a CGI-TS Change score of 1 \[very much improved\] or 2 \[much improved\] at Week 8. Response will be considered as missing only if both YGTSS TTS and CGI-TS change score are missing. As long as one of them is non-missing, response outcome will be determined based on the non-missing score.

Time frame:
Week 8
Reported as:
Number · Percentage of Responders
Response Rate
Percentage of RespondersAripiprazole Low DoseAripiprazole High DosePlacebo
Response Rate73.888.654.8
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0835 (P-value derived from Cochran-Mantel-Haenszel (CMH) General Association Test adjusting for region and weight group.) · Response ratio: 1.36 · 95% CI 0.98 to 1.88Response ratio \> 1 favors aripiprazole.
  • Aripiprazole High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0014 (P-value derived from CMH General Association Test adjusting for region and weight group.) · Response ratio: 1.61 · 95% CI 1.20 to 2.16Response ratio \> 1 favors aripiprazole.
SecondaryTreatment Discontinuation Rate

Treatment discontinuation rate will be calculated as the number of discontinued participants (ie, those who were withdrawn from the trial without completing the Week 8 visit) over the number of all randomized participants.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Treatment Discontinuation Rate
Percentage of participantsAripiprazole Low DoseAripiprazole High DosePlacebo
Treatment Discontinuation Rate4.522.54.5
Statistical analysis
  • Aripiprazole Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9187 (Discontinuation ratio \< 1 favors aripiprazole. P-value derived from CMH General Association Test adjusting for region and weight group.) · Discontinuation ratio: 1.16 · 95% CI 0.19 to 7.05
  • Aripiprazole Low Dose vs Placebo · Regression, Cox · p = 0.9576 (Hazard ratio \< 1 favors aripiprazole. P-value derived from Cox proportional hazard regression adjusting for region and weight group.) · Hazard ratio (hr): 1.05
  • Aripiprazole High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0132 (Discontinuation ratio \< 1 favors aripiprazole. P-value derived from CMH General Association Test adjusting for region and weight group.) · Discontinuation ratio: 4.06 · 95% CI 1.10 to 14.95
  • Aripiprazole High Dose vs Placebo · Regression, Cox · p = 0.0278 (Hazard ratio \< 1 favors aripiprazole. P-value derived from Cox proportional hazard regression adjusting for region and weight group.) · Hazard ratio (hr): 5.51

Adverse events

Collected over Adverse events (AEs) were recorded from the time of signing the informed consent up to 30 days after the last trial visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole Low Dose—0/44 (0%)21/44 (47.7%)
Aripiprazole High Dose—0/45 (0%)29/45 (64.4%)
Placebo—0/44 (0%)8/44 (18.2%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAripiprazole Low DoseAripiprazole High DosePlacebo
SedationNervous system disorders8/444/451/44
FatigueGeneral disorders3/447/450/44
SomnolenceNervous system disorders5/447/451/44
LethargyNervous system disorders0/445/450/44
Increased appetiteMetabolism and nutrition disorders4/443/451/44
NauseaGastrointestinal disorders3/444/451/44
NasopharyngitisInfections and infestations3/444/450/44
HeadacheNervous system disorders3/444/451/44
Upper respiratory tract infectionInfections and infestations1/441/453/44
VomitingGastrointestinal disorders2/443/452/44

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole Low DoseAripiprazole High DosePlaceboTotal
Mean11.1 ± 3.111.8 ± 2.811.6 ± 2.811.5 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole Low DoseAripiprazole High DosePlaceboTotal
Female8101129
Male363533104
08

Study locations

75 sites
  • Dothan, Alabama, United States
  • Goodyear, Arizona, United States
  • Tucson, Arizona, United States
  • Corona, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Santa Ana, California, United States
  • Wildomar, California, United States
  • Norwich, Connecticut, United States
  • Bradenton, Florida, United States
  • Gainsville, Florida, United States
  • Leesburg, Florida, United States
  • Maitland, Florida, United States
  • Miami, Florida, United States
  • Orange City, Florida, United States
  • Orlando, Florida, United States
  • St Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Columbus, Georgia, United States
  • Savannah, Georgia, United States
  • Naperville, Illinois, United States
  • Indianapolis, Indiana, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • Louisville, Kentucky, United States
  • Waldorf, Maryland, United States
  • Bloomfield Hills, Michigan, United States
  • Mt Arlington, New Jersey, United States
  • Summit, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Manhasset, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Staten Island, New York, United States
  • Durham, North Carolina, United States
  • Cleveland, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Mt. Pleasant, South Carolina, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Orem, Utah, United States
  • Salt Lake City, Utah, United States
  • Charlottesville, Virginia, United States
  • Henrico, Virginia, United States
  • Norfolk, Virginia, United States
  • Bellevue, Washington, United States
  • Bothell, Washington, United States
  • Middleton, Wisconsin, United States
  • Kentville, Nova Scotia, Canada
  • Parry Sound, Ontario, Canada
  • Toronto, Ontario, Canada
  • Whitby, Ontario, Canada
  • Dresden, Germany
  • Freiburg, Germany
  • Mannheim, Germany
  • Wurzburg, Germany
  • Budapest, Hungary
  • Szeged, Hungary
  • Catania, Italy
  • Milano, Italy
  • Roma, Italy
  • Durango, Mexico
  • Leon, Mexico
  • Mexico City, Mexico
  • Bucharest, Romania
  • Iasi, Romania
  • Madrid, Spain
  • Goteborg, Sweden
09

References and documents

Publications

  • Sallee F, Kohegyi E, Zhao J, McQuade R, Cox K, Sanchez R, van Beek A, Nyilas M, Carson W, Kurlan R. Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017 Nov;27(9):771-781. doi: 10.1089/cap.2016.0026. Epub 2017 Jul 7. PubMed 28686474 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 6 months after primary completion. A results delay was requested in Jul 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2012
First posted
Nov 16, 2012
Start
Nov 2012
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Results delay requested
Jul 28, 2014
Results first posted
Feb 13, 2015
Last update
Feb 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01727700
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Nov 2012
Primary completion
Aug 2013
Completion
Sep 2013
Results posted
Feb 13, 2015
Last update
Feb 13, 2015

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion